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94 Session: Disease & Treatmentmorphogenic proteins (BMPs) have also been tested as an adjunct therapy to
accelerate the healing of fractures. BMP is an expensive therapy and has not
been approved by the FDA for fracture treatment, only for spinal fusion.
Clearly, there is an unmet clinical need of a less expensive adjunct therapy
for better clinical management of fracture non-union. As a water-soluble mono-
mer isolated from Salviae miltiorrhizae, tanshinol has been proved to be an
effective bone anabolic agent with a high therapeutic index. However, its
high water solubility and lack of chemical stability, has impeded its clinical
application. To address this issue, we have developed a tanshinol-loaded
bone-targeting liposome formulation (Tan-BTL). The objective of this study
was to examine the potential therapeutic effects of Tan-BTL on fracture repair
in mice.
Methods: The bone-targeting liposome (BTL) was labelled by rhodamine B and was
used for a hydroxyapatite affinity test in vitro and a bone tissue targeting test in
vivo. The BTL was labelled by IRdye 800CW for the observation of its distribution
and retention time in the fracture site of mice. Tan-BTL (equivalent tanshinol dose
5 mg/kg, local administration once/week) was used for the treatment of a delayed
fracture healing mouse model (induced by daily administration of prednisone at
12 mg/kg for 64 days). Planar X ray image monitored the healing process of the
model for 64 days and the callus was analysed by micro-CT at the 18th day after
fracture.
Results: Tan-BTL demonstrated significant hydroxyapatite affinity in vitro. His-
tological analysis of the distal femur after local administration of the formula-
tion reveals robust targeting and retention at the growth plate, the trabecular
bone, the cortical bone, and bone lacuna. A near infrared imaging analysis
further confirmed BTL could concentrate on the fracture site of mice and be
retain there up to 20 days after local injection. When tested in a delayed frac-
ture healing mouse model (induced by daily administration of prednisone at
12 mg/kg for 64 days), micro-CT and planar X-ray imaging analysis of the callus
tissue suggests that Tan-BTL increased callus BV/TV by 54% in a femur fracture
of glucocorticoid-treated mice at the 18th day and shortened the fracture heal-
ing time from >64 days to 42 days when compared to glucocorticoid-treated
mice without treatment.
Conclusion: These results support BTL as a promising targeted drug delivery sys-
tem for local delivery of low molecular weight bone anabolic agents. Specifically,
the Tan-BTL formulation tested could be a simple, safe, and effective non-invasive
strategy for the treatment of bone fracture non-union.
http://dx.doi.org/10.1016/j.jot.2016.06.080231
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Introduction: Chronic inflammation is thought to cause ligamentum flavum (LF)
degeneration and hypertrophy in lumbar spinal canal stenosis (LSCS). Angiopoie-
tin-like protein 2 (Angptl2) is highly expressed in hypertrophied LF. Angptl2 regu-
lates interleukin-6 (IL-6) expression in various tissues, thus we investigated
whether IL-6 is expressed in hypertrophied LF and, if so, whether Angptl2 induces
IL-6 expression in LF fibroblasts.
Patients and Methods: LF tissue was obtained from LSCS patients and non-LSCS
patients. Polymerase chain reaction (PCR) for Angptl2 and IL-6 genes, and immu-
nohistochemistry for IL-6 protein were performed in LF tissue. Fibroblasts from
LF tissue were used for in vitro experiments. After Angptl2 recombinant protein
treatment, NF-kB activation and IL-6 expression in LF fibroblasts were
investigated by immunocytochemistry, PCR, and enzyme-linked immunosorbent
assay.
Results: IL-6 mRNA expression was increased in hypertrophied LF tissue from
LSCS patients and positively correlated with LF thickness and Angptl2 mRNA
expression. IL-6 protein was highly expressed in LF fibroblasts in hypertrophied
LF tissue. In vitro experiments demonstrated Angptl2 stimulation promoted
NF-kB nuclear translocation and induced IL-6 expression and secretion in LF
fibroblasts.
Discussion and Conclusion: This study provides evidence that Angptl2 could be a
key molecule causing and promoting inflammation in LF tissue by activating IL-6
expression. IL-6 mRNA expression and IL-6-expressed fibroblasts were increased
in hypertrophied LF compared with non-hypertrophied LF. Also, the expression
was positively correlated with LF thickness and Angptl2 expression. Our in vitro ex-
periments show that Angptl2 was able to elevate IL-6 expression via integrin a5b1/
NF-kB signalling in LF fibroblasts. Angptl2 could promote inflammation in LF tissue
by increasing IL-6 expression and secretion, resulting in LF degeneration and hy-
pertrophy in LSCS patients. Anti-Angptl2 treatment could serve as a target in novel
strategies for preventing LSCS and treating it.
http://dx.doi.org/10.1016/j.jot.2016.06.081246
MESENCHYMAL STEM CELLS PROMOTE VASCULOGENIC MIMICRY IN PROSTATE
CANCER THROUGH SDF-1/ CXCR4 AXIS AND PI3K/Akt PATHWAY
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Background: Prostate cancer frequently metastasizes to the bone and the interac-
tion between cancer cells and the bone microenvironment has proven to be crucial
in the establishment of new metastases. Mesenchymal stromal cells (MSCs) in bone
marrow may enhance tumour metastasis through secreting various cytokines that
can regulate the behaviour of neighbouring cells. The term vasculogenic mimicry
(VM) refers to the unique capability of aggressive tumour cells to mimic the
pattern of embryonic vasculogenic networks. VM has been described in prostate
cancer and some other highly aggressive tumours and is associated with tumour
cell migration and invasion. However, the relationship between MSCs in their
native bone marrow microenvironment and VM formation is not clear. Here we
investigated the possible role of MSCs in VM by Prostate cancer cell lines, focusing
primarily on the SDF-1/CXCR4 Axes and PI3K/Akt pathway.
Subjects and Methods: We studied the underlying mechanisms of VM in prostate
cancer via the 3D culture system in vitro of PC-3 cells, expression of SDF-1,
CXCR4, Akt, p-Akt and VE-cadherin proteins/mRNAs determined by ELISA, immuno-
fluorescence, western blotting, and qRT-PCR, respectively.
Results: In this study, we show the effects of hMSCs on cancer cells are mediated
through a secreted factor(s). In addition to enhanced proliferation when in co-cul-
ture with hMSCs, PC-3 cells were found to have increased the VM formation and
CXCR4 expression in vitro. In addition, knocking down of CXCR4 using RNA interfer-
ence or inhibition of CXCR4 function by an antagonist AMD3100 blocked hMSC-
induced VM formations of PC-3 cells. Furthermore, hMSCs increased phosphoryla-
tion of Akt. Additionally, blocking PI3K/Akt Pathway using a PI3K inhibitor
LY294002 decreased hMSCs induced VM formations of PC-3 cells. Under in vivo con-
ditions, tumour growth and VM formation was promoted by MSCs in nude mice.
Discussion and Conclusion: To our knowledge, this is the first report discussing the
relationship between MSCs and VM of cancer cells. This study establishes that MSCs
in the bone microenvironment might promote the VM formations of Prostate can-
cer and points to SDF-1/CXCR4 axis and PI3K/Akt pathway as a potential target for
therapeutic intervention. Better understanding of the mechanisms involved in this
tumour stoma cell interaction may provide novel targets for the development of
treatment strategies for prostate to bone metastasis.
http://dx.doi.org/10.1016/j.jot.2016.06.082248
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Object: Hip trochanter (TRO) and intertrochanter (INT) sub-regions have impor-
tant clinical relevance to subtrochanteric and intertrochanteric fractures, but
have rarely been studied by genome-wide association studies (GWASs).
Subjects and Methods: Aiming to identify genomic loci associated with BMD vari-
ation at TRO and INT regions, we performed a GWAS utilising the Framingham heart
study (FHS, NZ6,912) as a discovery sample, and utilised the Women’s health
initiative (WHI) African-American sub-sample (NZ845), WHI Hispanic sub-sample
(NZ446), and Omaha osteoporosis study (NZ963), for replication.
Results: Combining the evidence from both discovery and replication samples, we
identified one novel locus, 3q13.32 (rs1949542, discovery pZ6.16x10-8, replica-
tion pZ2.86x10-4 for INT-BMD; discovery pZ1.35x10-7, replication pZ4.16x10-4
